Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory Neuroblastoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT00450307
What this trial is testing

Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed Neuroblastoma

Who this might be right for
Neuroblastoma
Memorial Sloan Kettering Cancer Center 32
Early research (Phase 1)Study completedNCT02076906
What this trial is testing

MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors

Who this might be right for
Relapsed Pediatric Solid TumorsRefractory Pediatric Solid TumorsRhabdomyosarcoma+7 more
AeRang Kim 7
Testing effectiveness (Phase 2)Looking for participantsNCT05754684
What this trial is testing

Quadruple Immunotherapy for Neuroblastoma

Who this might be right for
Neuroblastoma Recurrent
Hong Kong Children's Hospital 29
Testing effectiveness (Phase 2)Active Not RecruitingNCT03213652
What this trial is testing

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmMalignant Solid NeoplasmRecurrent Ependymoma+30 more
National Cancer Institute (NCI) 13
Testing effectiveness (Phase 2)Study completedNCT00010283
What this trial is testing

Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon

Who this might be right for
Breast CancerChronic Myeloproliferative DisordersGestational Trophoblastic Tumor+9 more
Fred Hutchinson Cancer Center
Testing effectiveness (Phase 2)Looking for participantsNCT06450041
What this trial is testing

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

Who this might be right for
Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium 62
Early research (Phase 1)Active Not RecruitingNCT01822652
What this trial is testing

3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN

Who this might be right for
Neuroblastoma
Baylor College of Medicine 11
Early research (Phase 1)Ended earlyNCT02337309
What this trial is testing

SF1126 for Patients With Relapsed or Refractory Neuroblastoma

Who this might be right for
Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium 4
Testing effectiveness (Phase 2)Active Not RecruitingNCT02650401
What this trial is testing

Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

Who this might be right for
Solid TumorsCNS Tumors
Hoffmann-La Roche 69
Testing effectiveness (Phase 2)Looking for participantsNCT07502287
What this trial is testing

Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma

Who this might be right for
Relapsed NeuroblastomaRefractory NeuroblastomaHigh-Risk Neuroblastoma+1 more
Beijing Biotech 36
Early research (Phase 1)Study completedNCT01059071
What this trial is testing

Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide

Who this might be right for
Neuroblastoma
Giselle Sholler 21
Testing effectiveness (Phase 2)Active Not RecruitingNCT03794349
What this trial is testing

Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma

Who this might be right for
High Risk NeuroblastomaRecurrent NeuroblastomaRefractory Neuroblastoma
Children's Oncology Group 94
Very early researchLooking for participantsNCT07067346
What this trial is testing

Safety & Efficacy of IR-101 in Relapsed/Refractory Neuroblastoma

Who this might be right for
Neuroblastoma
Sichuan University 10
Large-scale testing (Phase 3)Study completedNCT00799461
What this trial is testing

Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia in Remission+89 more
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium 1,337
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07444918
What this trial is testing

Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors

Who this might be right for
Relapsed or Refractory Pediatric Malignant Solid Tumors (Including Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma)
Tianjin Medical University Cancer Institute and Hospital 33
Early research (Phase 1)Looking for participantsNCT07027748
What this trial is testing

Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma

Who this might be right for
NeuroblastomaNeuroblastoma RecurrentRelapsed Neuroblastoma+1 more
Steven DuBois, MD 18
Early research (Phase 1)Study completedNCT00450827
What this trial is testing

Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma

Who this might be right for
Neuroblastoma
Memorial Sloan Kettering Cancer Center 25
Testing effectiveness (Phase 2)Study completedNCT03213665
What this trial is testing

Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmAnn Arbor Stage III Hodgkin LymphomaAnn Arbor Stage III Non-Hodgkin Lymphoma+38 more
National Cancer Institute (NCI) 20
Testing effectiveness (Phase 2)Study completedNCT00436852
What this trial is testing

ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment

Who this might be right for
Disseminated NeuroblastomaRecurrent Neuroblastoma
Children's Oncology Group 92
Early research (Phase 1)Looking for participantsNCT05400603
What this trial is testing

Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma

Who this might be right for
NeuroblastomaRefractory NeuroblastomaRelapsed Neuroblastoma+2 more
Emory University 24
Next Page